MEDIA
Want to find out what’s happening with us?
Here’s the latest buzz…
MAY, 2024
Somerset Pharma announces yet another CGT product approval for Atropine Sulfate Ophthalmic Solution
We are pleased to share that we have received one more approval from USFDA for Atropine Sulphate Ophthalmic Solution generic equivalent to Isopto Atropine®.
This product launch is one of the many anticipated to be launched by Somerset from its own manufacturing facility. The launch of Atropine Sulfate 1% – 5 mL bottle underscores the company’s commitment to making quality generics available at affordable prices. Somerset has received CGT status for the product and will be among the few generics in the market. We are now poised to launch a pipeline of products post approval, from the same facility.
“We are delighted to share that this approval and subsequently the launch went through in record time, thanks to the tireless efforts of the team. The pipeline of products from this manufacturing facility will go a long way in achieving our vision of delivering high-quality generics at affordable prices, for the benefit of our healthcare partners and their patients.”
– Dr. Veerappan Subramanian
Chairman & CEO, Somerset Pharma
Atropine Sulphate Ophthalmic Solution is used in pupil dilation during eye examinations and is also indicated for the treatment of amblyopia (lazy eyes) and various eye conditions, including cycloplegia.
We take this opportunity to thank our healthcare partners for your constant support and faith in the company. We look forward to achieving and celebrating many new milestones together.